Exact Sciences' Q1 Loss Narrows

Exact Sciences Announces First-Quarter 2024 Results

(Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million ...

Exact Sciences Announces First-Quarter 2024 Results

Net loss was $110 million, or $0.60 per share, compared to a net loss of $74 million, or $0.42 per share; EBITDA was $(47) million and adjusted ...

Exact Sciences Q1 Net Loss Narrows - Quick Facts - RTTNews

Exact Sciences Corp. (EXAS) reported a first quarter net loss of $1.9 million, or $0.07 per share, compared to a net loss of $4.2 million, ...

Exact Sciences - FY21 Outlook In Line - MarketScreener

Exact Sciences late Tuesday reported a Q1 net loss of $0.18 ... Exact Sciences : Q1 Loss Narrows, Revenue Gain Also Tops Estimates; FY21 Outlook In Line.

Exact Sciences Announces Third-Quarter 2024 Results

Net loss was $38 million, or $0.21 per basic and diluted share, a reduction of $39 million, or $0.21 per basic and diluted share; Adjusted ...

Exact Sciences Corporation (NASDAQ:EXAS) First-Quarter Results

If met, it would imply a solid 12% increase on its revenue over the past 12 months. The loss per share is expected to greatly reduce in the near ...

Exact Sciences Announces Third-Quarter 2024 Results

... first publication on the Oncodetect™ test, its molecular residual disease and recurrence monitoring test Exact Sciences Corp. (Nasdaq: EXAS) ...

Exact Sciences stock tumbles despite strong cancer detection sales

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company's executives still ...

Exact Sciences Announces First Quarter 2023 Results

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated ...

Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook

Exact Sciences reported a third-quarter loss of 21 cents a share on revenue of $708.7 million. Analysts were expecting a loss of 21 cents a ...

Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y

Exact Sciences Corporation EXAS reported a net loss of 27 cents per share for fourth-quarter 2023, a significant improvement from the ...

Exact Sciences Announces Second-Quarter 2024 Results

MADISON, Wis., July 31, 2024 — Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced ...

Exact Sciences Announces First Quarter 2023 Results

(Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 ...

Exact Sciences' Q1 loss matches expectations but revenue comes in ...

Madison's Exact Sciences Corp. reported a first-quarter loss of $110.2 million Wednesday, according to the Wisconsin State Journal.

Exact Sciences Announces Preliminary Fourth Quarter 2023 Results

7, 2024 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that ...

Exact Sciences Corporation Provides Earnings Guidance for the ...

Exact Sciences Corporation provided earnings guidance for the first quarter and full year of 2023 ... Loss Narrows, Revenue Rises; Shares ...

Exact Sciences' First-Quarter Results Show Its Strength Under ...

On May 4, healthcare diagnostics company Exact Sciences (EXAS -2.17%) delivered its first-quarter numbers, reporting revenues of $402 million, a ...

UPDATE: Exact Sciences Reports Q1 Revenues of $4.3M

NEW YORK(GenomeWeb) – Exact Sciences today reported $4.3 million in revenues for the first quarter, beating the consensus Wall Street estimate ...

Guardant Health Pops 13% On An 'Impressive' Beat Following Exact ...

Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop · Guardant Health Stock: Narrow Losses · 20% Growth In 2025.

Exact Sciences Announces First Quarter 2022 Results

Total first quarter revenue of $487M, including Screening revenue of $307M, Precision Oncology revenue of $153M, and COVID-19 testing ...